ReviewChemistry, an Asian journal2019
New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections.
Review in Chemistry, an Asian journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 216 citations in OpenAlex.
- Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.Pharmacological research · 2020Trial
- On the Verge of the 3000th Publication: Reflections on Deceptions, Successes and Perspectives.Molecules (Basel, Switzerland) · 2026Article
- Metal-decorated graphdiyne nanocarriers for favipiravir delivery: a DFT investigation.Nanoscale advances · 2026Article
- Therapeutic potential of allicin against viral infections: Mechanisms and safety profile (Review).Experimental and therapeutic medicine · 2026Review
- Generation of a 3-Allyl/Propanylthiomethyl Ketene and their [4+2] Cycloadditions With 1,3-Diazabuta-1,3-dienes: Synthesis of 5-Allyl/propargyl-thio methyl Pyrimidinones.Chemistry & biodiversity · 2026Article
- Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice.Frontiers in pharmacology · 2025Article
- Advancements in the development of antivirals against SARS-Coronavirus.Frontiers in cellular and infection microbiology · 2025Review
- Innovative anti-proliferative effect of the antiviral favipiravir against MCF-7 breast cancer cells using green nanoemulsion and eco-friendly assessment tools.Scientific reports · 2024Article
- Metabolic RNA labeling in non-engineered cells following spontaneous uptake of fluorescent nucleoside phosphate analogues.Nucleic acids research · 2024Article
- POxload: Machine Learning Estimates Drug Loadings of Polymeric Micelles.Molecular pharmaceutics · 2024Article
- Molecular modeling of some commercially available antiviral drugs and their derivatives against SARS-CoV-2 infection.Narra J · 2024Article
- Marine Brown Algae-Derived Compounds as Potential Inhibitors of Japanese Encephalitis Virus RNA-Dependent RNA Polymerase.Marine drugs · 2024Article
- Favipiravir, an antiviral drug, in combination with tamoxifen exerts synergistic effect in tamoxifen-resistant breast cancer cells via hTERT inhibition.Scientific reports · 2024Article
- Immunization against Medically Important Human Coronaviruses of Public Health Concern.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Review
- 1-Sulfonyl-3-amino-1ACS omega · 2023Article
- Electrochemical sensor for simultaneous determination of antiviral favipiravir drug, paracetamol and vitamin C based on host-guest inclusion complex of β-CD/CNTs nanocomposite.Scientific reports · 2023Article
- Extracts ofPharmaceutical biology · 2023Article
- LC-MS/MS Method Development and Validation for Determination of Favipiravir Pure and Tablet Dosage Forms.Turkish journal of pharmaceutical sciences · 2023Article
- Recent Advances in Molecular Mechanisms of Nucleoside Antivirals.Current issues in molecular biology · 2023Review
- Incorporation ofInternational journal of molecular sciences · 2023Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eight different compounds, all nucleoside analogues, could presently be considered as potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic fever virus (HFV) infections. They can be considered as either (i) adenine analogues (3-deazaneplanocin A, galidesivir, GS-6620 and remdesivir) or (ii) guanine analogues containing the carboxamide entity (ribavirin, EICAR, pyrazofurin and favipiravir). All eight owe their mechanism of action to hydrogen bonded base pairing with either (i) uracil or (ii) cytosine. Four out of the eight compounds (galidesivir, GS-6620, remdesivir and pyrazofurin) are C-nucleosides, and two of them (GS-6620, remdesivir) also contain a phosphoramidate part. The C-nucleoside and phosphoramidate (and for the adenine analogues the 1'-cyano group as well) may be considered as essential attributes for their antiviral activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.